Coronavirus vaccine: India can lead in making COVID-19 vaccine in cheap rates

Coronavirus vaccine: India can lead in making COVID-19 vaccine in cheap rates

Coronavirus vaccine: India can lead in making COVID-19 vaccine in cheap rates

Hello visitors, in the whole world about 3,740,586 people are infected with the Coronavirus and about 2,584,81 deaths happened across the globe. The Havoc of Coronavirus is not stopping many countries along with their scientist, medicine companies all are trying to pause coronavirus outbreak and trying to make its vaccines.

Plasma Therapy

The world is looking towards India for coronavirus vaccines:

India is the Powerhouse for vaccine manufacturing the whole world had an eye on India for the COVID-19 vaccine. India produces 60% of the world vaccine and accounts for 60 to 80% of the United Nations annual vaccine procurement. Many Indian companies help over the years to produce and distribute vaccines to the world.


   Last month UN Secretary Mike Pompeo TOI that US and India are working together on coronavirus therapies and vaccines. It will be a great challenge for Indian companies to produce Vaccine of Coronavirus as it is an unknown challenge for the whole globe.


   In India at present there are vaccines makers such as Bharat Biotech, Serum Institute of India, and Zydus that are competing to develop coronavirus vaccine. India will be the only country that can sell coronavirus vaccine in the lowest possible prices due to its productivity ability adjunct professor and researcher in bioethics at Bengaluru’s Yenepoya University Anand Bhan said.


Italy to claim the world's first COVID-19 vaccine according to a report:

Italy has claimed that it has been successful in developing vaccines for the Coronavirus and it announced that it works on humans according to Arab news.


   As per test carried out at Rome’s infectious disease Spallanzani Hospital, the Coronavirus vaccine as antibodies that are generated in mice that also work on human cells reported CNBC TV 18.


   Research and scientist experimented with the vaccine on my which had been successful leaders antibody is that can have blocked the virus from infecting the human cells.


    Scientists observe that 5 candidates generated a large number of antibodies and selected 2 of the best results according to the reports. All the vaccine candidates based on their genetic material of DNA protein spike.


Pfizer candidates start human trials coronavirus vaccine:

Pfizer, an American multinational pharmaceutical company has started Phase 1 and phase 2 clinical trial on mRNA vaccine candidates today. The company has reported that it is working with collaboration with BioNTech, a German Biotech company for developing this vaccine.